You are here: Industry Insights > diabetes

News List

Social & Health Research Center and Quest Diagnostics Team Up to Address Childhood Hunger and Obesity Exacerbated by COVID-19 in Underserved Communities prnewswire
May 25, 2021
Childhood obesity has disproportionately affected Hispanic and Black communities as a result of negative social determinants of health for years.
COVID-19 to have long-term impact on global diabetes market: GlobalData expresspharma
May 24, 2021
As diabetes case numbers are expected to be further fuelled by COVID-19, and as the pathophysiology of COVID-19 induced diabetes is further explored, there will be more patients in need of targeted therapeutics.
Global diabetes therapeutic market has grown sixfold in last two decades: GlobalData expresspharma
May 20, 2021
The market has been a lucrative space for drug developers, as the disease is highly prevalent and patient numbers are expected to continue increasing in the foreseeable future.
FDA approves AstraZeneca’s Farxiga for chronic kidney disease treatment pharmaceutical-technology
May 06, 2021
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Farxiga (dapagliflozin) for treating chronic kidney disease (CKD) in patients who are at the risk of progression with and without type-2 diabetes.
Med7 LLC, announce the completion of a safety and efficacy study using Hempzorb81TM Full Spectrum Hemp Oil in patients with Type II Diabetes prnewswire
April 30, 2021
Med7, LLC and HempCo, Inc. announce the completion of a human clinical study in patients with Type II Diabetes using Purzorb? technology, now trademarked as Hempzorb81TM. "
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes americanpharmaceuticalreview
April 14, 2021
vTv Therapeutics Inc. a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
Welldoc and Dexcom Expand Strategic Partnership to Integrate Platforms and Offer Integrated Type 2 Diabetes Management Solution americanpharmaceuticalreview
April 07, 2021
Welldoc announced the first customer for a new integrated offering to drive improved health for people with Type 2 diabetes.
FDA refuses Novo Nordisk’s once-weekly semaglutide pharmatimes
March 25, 2021
Novo Nordisk has received a refusal to file letter from the US Food and Drug Administration (FDA) for a label expansion application for semaglutide.
Frontline charities sign open letter backing COVID-19 vaccination drive pharmatimes
March 17, 2021
A partnership of frontline health charities has signed an open letter encouraging people with underlying conditions to book in for a COVID-19 vaccine.
Lilly, Biolojic to develop antibody therapies for diabetes treatment pharmaceutical-business-review
March 15, 2021
?Eli Lilly and Company has signed a research collaboration and license agreement with Biolojic Design to discover and develop therapies for diabetes treatment.